The RELIEVE-HF trial of the Ventura Shunt System includes patients with reduced and preserved left ventricular function etiologies for heart failure
News | Heart Failure
V-Wave Completes Enrollment in the RELIEVE-HF Randomized Double-Blind Controlled Trial of Interatrial Shunting for Heart Failure

October 28, 2022 — V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective, randomized, double ...

Home October 28, 2022
Home
SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal clinical trial.
News | Drug-Eluting Balloons
MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval

October 28, 2022 — SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device ...

Home October 28, 2022
Home
Elite young athletes are set to benefit from a novel screening tool with the potential to change clinical practice by ruling out a serious heart condition frequently misdiagnosed. #GabeMillane #Batavia #BataviaBulldogs #BataviaFootball
News | Pediatric Cardiology
Rising Star Footballers Among Young Athletes to Benefit From New Screening Tool

October 27, 2022 — Elite young athletes are set to benefit from a novel screening tool with the potential to change ...

Home October 27, 2022
Home
Barostim Baroreflex Activation Therapy is the world’s first FDA-approved device which uses the power of the brain and nervous system to improve symptoms of progressive heart failure
News | Heart Failure
Allegheny Health Network Cardiovascular Institute First in Pittsburgh to Implant Groundbreaking Neuromodulation Device as Alternative Therapy for Heart Failure Patients

October 27, 2022 — Vascular surgeons from Allegheny General Hospital (AGH) Cardiovascular Institute, the flagship ...

Home October 27, 2022
Home
The research team members say they have long known that infections such as the flu can increase risk for heart disease and heart attack, but the sharp rise in heart attack deaths is like nothing seen before.
News | Coronavirus (COVID-19)
COVID-19 Surges Linked to Spike in Heart Attacks

October 27, 2022 — New data analysis from the Smidt Heart Institute at Cedars-Sinai found that deaths from heart attacks ...

Home October 27, 2022
Home
Clinical study evaluates treatment for endovascular aortic arch repair
News | Endovascular Aortic Repair
UH Harrington Heart and Vascular Institute Performs First TRIOMPHE Study Case in Northeast Ohio

October 26, 2022 — Thousands of people have new hope for treatment of thoracic aortic arch disease and University ...

Home October 26, 2022
Home
Alex Carll, assistant professor in the UofL Department of Physiology, front, with Matthew Nystoriak, associate professor of medicine. (UofL Photo)
News | Atrial Fibrillation
UofL Researchers Discover E-Cigarettes Cause Cardiac Arrhythmias

October 26, 2022 — A new study from University of Louisville researchers in the Christina Lee Brown Envirome Institute ...

Home October 26, 2022
Home
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support
News | Intra-Aortic Balloon Pumps (IABP)
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare

October 26, 2022 — Abiomed (Nasdaq: ABMD) announces a new program to address healthcare disparities in underserved ...

Home October 26, 2022
Home
Videos | TCT
VIDEO: Precision Cardiovascular Medicine: The Next Frontier in Patient Care and Innovation

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional ...

Home October 26, 2022
Home
CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.
News | Holter Monitoring Systems
RhythMedix Expands Monitoring Capabilities of Its RhythmStar System, the First Wearable Cardiac Monitor with Built-In Cellular Connectivity

October 25, 2022 — RhythMedix, a leader in remote cardiac monitoring and proprietary arrhythmia detection algorithms ...

Home October 25, 2022
Home
Asher Kimchi, MD: 1946-2022
News | Cardiovascular Business
Founder, Medical Co-Director of Preventive and Consultative Heart Center of Excellence at Smidt Heart Institute Remembered

October 24, 2022 — Asher Kimchi, MD, clinical chief of Cardiology, vice-clinical chief of the Department of Medicine ...

Home October 24, 2022
Home
CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.
News | Hypertension
CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

October 24, 2022 — CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly ...

Home October 24, 2022
Home
Donald Baril, MD, a Leading Vascular Surgeon in the Smidt Heart Institute, Named Director of the Vascular Surgery Fellowship Program
News | Cardiovascular Surgery
Vascular Surgeon to Lead, Train Fellows

October 24, 2022 The Smidt Heart Institute at Cedars-Sinai has selected leading vascular surgeon Donald Baril, MD, as ...

Home October 24, 2022
Home
Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated announced submission of pivotal clinical data from the AcQForce Flutter trial
News
Acutus Medical Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter and System

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps.
News | Cardiogenic Shock
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

October 21, 2022 — Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post ...

Home October 21, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now